Peptide receptor-mediated radionuclide therapy for treatment of the somatostatin receptor-positive tumors

1306 Learning Objectives 1. To review of the clinical indications of the Yttrium-90 DOTATOC, 177 Lu-DOTATATE, 111 In-DOTATATE therapy. 2. To review the advantages and disadvantages of Yttrium-90 DOTATOC, 177 Lu-DOTATAT, 111 In-DOTATATE therapy. 1. Review of the molecular aspects of somatostatin receptors and peptide ligands 2. Review of the technical aspects of peptide receptor-mediated radionuclide therapy receptors. 3. Discuss the clinical utility of Yttrium-90 DOTATOC, 177 Lu-DOTATATE, 111 In-DOTATATE therapy for treatment of the somatostatin receptor-positive tumors. 4. Discuss the side-effects of the Peptide receptor-mediated radionuclide therapy and efforts to prevent the toxicity SUMMARY Molecular imaging and therapy have found widespread application in evaluation and treatment of cancers. Peptide receptor-mediated radionuclide therapy has shown to be very effective in management of somatostatin receptor-positive tumors. Yttrium-90 DOTATOC, 177 Lu-DOTATATE and 111 In-DOTATATE are the therapeutic agents which show very promising results. Their associated marrow and renal toxicity requires careful evaluation. They can be administered with a low risk of myelotoxicity, although the cumulative radiation dose to the kidneys is a limiting factor. Several different ways have developed to decrease the renal toxicity which will be discussed during the presentation.